The largest database of trusted experimental protocols

4 protocols using anti cd69 bv421

1

HLA-DP-expressing Jurkat reporter assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
HLA-DP-expressing Jurkat E6.1 cells were co-incubated with NKp44ζ+, NKp46ζ+ Jurkat reporter cells or untransduced Jurkats at an effector to target ratio of 1:10 for 5 h at 37 °C/5% CO2. For peptide-pulsing experiments, HLA-DP-expressing Jurkat E6.1 cell lines were washed twice with serum-free medium and pulsed with 100 µM CLIP peptide (sequence: LPKPPKPVSKMRMATPLLMQALPM; GenScript) or an equivalent amount of DMSO for 18 h at 37 °C/5% CO2. After peptide pulsing, JE6.1-DP cells were washed and co-incubated with Jurkat reporter cell lines. Subsequently, cells were stained with anti-CD3-BUV737 (BD Biosciences), anti-NKp44-PE (Biolegend) or anti-NKp46-PE (BD Biosciences), anti-CD69-BV421 (Biolegend), LiveDead NearIR (Life Technologies) and anti-HLA-ABC-APC (Biolegend), to discriminate between HLA-DP-expressing JE6.1 and Jurkat reporter cells, for 30 min at 4 °C. Cells were fixed with 4% PFA and analyzed on a BD LSR Fortessa. HLA-DP and CLIP surface expression of JE6.1-DP cells was assessed by staining CLIP-pulsed and DMSO-pulsed JE6.1-DP cells with anti-CD3-BUV737 (BD Biosciences), anti-HLA-DP-APC (Leinco Technologies), anti-CLIP-FITC (BD Biosciences) and LiveDead NearIR (Life Technologies) for 30 min at 4 °C. Cells were subsequently fixed and analyzed on a BD LSR Fortessa. (A detailed list of antibodies used is displayed in Supplementary Table 2.)
+ Open protocol
+ Expand
2

Antibodies for Cellular Immunoassays

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies were used for cellular assays: anti-HLA-ABC-APC (clone W6/32, eBioscience), anti-CD3-BU737 (clone UCHT1, BD Bioscience), anti-CD3-PerCyP.5.5 (clone UCHT1, BioLegend), anti-CD19-BV510 (clone HIB19, BioLegend), anti-CD56-BU395 (clone NCAM16.2, BD Bioscience), anti-CD16-BV785 (clone 3G8, BioLegend), anti-KIR2DL1/S1/L3/S3/L5/S5-PE (clone HP-MA4, eBioscience), anti-KIR2DL1/S1-PE (clone 11PB6, Miltenyi), anti-KIR2DL1-FITC (clone REA284, Miltenyi), anti-KIR2DL3-APC (clone DX27, Miltenyi), anti-KIR3DL1/S1-BV421 (clone DX9, BioLegend), anti-NKG2A-PE-Cy7 (clone Z199, Beckman), anti-NKG2D-APC (clone 1D11, BioLegend), goat anti-human IgG(Fc) F(ab´)-PE (Life Technologies), anti-CD69-BV421 (clone FN50, BioLegend), anti-CD107a-BV421 (clone M4A3, BioLegend). For blocking assays we pre-incubated the samples with anti-HLA-C antibodies (clone 6A4, IgM, kindly provided by Prof. L. Moretta, Istituto Giannina, Genova, Italia) diluted 1/20 for 20 min at 37 °C.
+ Open protocol
+ Expand
3

KIR-Fc Binding and Jurkat Reporter Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
KIR-Fc staining was performed as described [12 (link),13 (link),24 (link)]. Measurement of KIR-Fc binding was assessed as percentage of PE-positive cells (SUP1). KIR Jurkat reporter cell assays were performed as described [16 (link)]. Briefly, peptide pulsed 221-TAPko-HLA-C∗03 : 04 cells were coincubated with Jurkat Reporter cells expressing KIR2DL3, with the intracellular tail exchanged through CD3ξ chain resulting in activation of the cell after ligand binding in a ratio of 1 : 10. After 5 h of incubation at 37°C/5%, CO2 cells were stained with anti-CD69-BV421 (Biolegend, Inc. San Diego, California, USA), anti-CD3-PerCP-Cy5.5 (Biolegend) and anti-KIR2DL3-APC (Miltenyi Biotec). Washed and fixed cells were analysed using flow cytometry (BD LSRFortessa: BD Biosciences Franklin Lakes, New Jersey, USA). Gates were set to only include CD3+/KIR2DL3+ cells. Activation of reporter cells was quantified as median MFI of CD69 expression normalized to background expression.
+ Open protocol
+ Expand
4

Autologous NK Cell Activation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
NK cells were isolated from cryopreserved PBMCs of autologous donors or individuals matched for HLA-Bw4/Bw6 and C1/C2 motifs to organoid donor, and stimulated as described above. WT and HLA-DPB1 KO organoids were expanded, stimulated with IFN-γ (200 U/mL, 72 hours) and dissociated to single cells. Prestimulated NK cells were resuspended in RPMI-1640/10% FBS at final concentration of 2×105 cells/mL. Cholangiocyte organoids and NK cells were distributed to the respective conditions at a E:T ratio of 1:10 and anti-CD107a-BV785 (BioLegend) was added. Plate-bound anti-NKp44 and PBS only served as positive and negative controls. Cells were incubated for 5 hours at 37°C/5% CO2, and subsequently stained with anti-CD3-BV510, anti-CD56-BV605, anti-CD16-FITC, anti-NKp44-AF647, anti-CD69-BV421 (all BioLegend) and LIVE/DEAD Fixable Near-IR Dead Cell Stain (Invitrogen). Cells were washed, fixed in 4% PFA and analysed at a BD LSRFortessa.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!